Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109446 | 0.85 | CA1 (0.40) | CA1CA2NOS2NOS3NOS1 | |
| SCHEMBL18109444 | 0.85 | CA1 (0.40) | CA1CA2NOS2NOS3NOS1 | |
| SCHEMBL1068024 | 0.85 | CA1 (0.38) | CA1CA2NOS2NOS3NOS1 | |
| SCHEMBL206673 | 0.85 | CA1 (0.38) | CA1CA2NOS2NOS3NOS1 | |
| SCHEMBL31054715 | 0.84 | CPB2 (0.35) | CA1CA2NOS2NOS3NOS1 | |
| SCHEMBL15705454 | 0.84 | CA1 (0.35) | CA1CA2NOS2NOS3NOS1 | |
| SCHEMBL15670490 | 0.84 | CA1 (0.35) | CA1CA2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1068022 | 0.83 | NOS2 (0.39) | CA1CA2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL15666248 | 0.83 | NOS2 (0.39) | CA1CA2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL15664934 | 0.82 | NOS2 (0.36) | CA1CA2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688156-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-26 | — | — | US | disclosed |
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | US | disclosed |
| US-12215111-B2 | Imidazopyridazine IL-17 inhibitor compounds | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-04 | — | — | US | disclosed |
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-24 | — | — | US | disclosed |
| WO-2024201322-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408529-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408847-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023049887-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049886-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA1 4430/4885CA2 4099/4885NOS2 872/4885 |
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | IL17A, IL23R, IL15 | CA1 4430/4885CA2 4099/4885NOS2 872/4885 |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA1 4430/4885CA2 4099/4885NOS2 872/4885 |
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA1 4430/4885CA2 4099/4885NOS2 872/4885 |
| US-12215111-B2 | Imidazopyridazine IL-17 inhibitor compounds | IL17A, IL23R, IL15 | CA1 4430/4885CA2 4099/4885NOS2 872/4885 |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA1 4430/4885CA2 4099/4885NOS2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.